Foresee Pharmaceuticals (TPEx: 6576) ("Foresee") announced today the acceptance of an abstract for presentation at ...
That’s how wilderness explorer John Dunn cheerfully described the second leg of “Journey North,” an 8,000-kilometre, 400-day ...
4d
Data highlights PYLARIFY’s ability to detect recurrent prostate cancer in patients with low PSAReal-world evidence of PYLARIFY’s effectiveness in ...
The way you see nutrition labels on food packaging is about to change. By 2025, new front-of-package labels will start ...
Featured data showcase the transformative potential of HSC gene therapy to enable cross-correction and restore enzymatic function in a variety of tissues and organs, including the CNSTOKYO, LONDON and ...
PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across its development programs will be included at ...
Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions ...
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and ...
AUSTIN, TX, USA and HAMILTON, Canada and SAN DIEGO, CA, USA I7, 2025 I Triumvira Immunologics, a clinical-stage company ...
NN, Inc.'s new CEO Harold Bevis, with significant turnaround experience, has initiated cost cuts. Click here to read why NNBR stock is a Strong Buy.
Got a tip? Send it to The Daily Beast here. ADVERTISEMENT ADVERTISEMENT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback